Management of INR 6.2
For a patient with an INR of 6.2 on warfarin who is not bleeding and has no high-risk bleeding factors, omit the next 1-2 doses of warfarin and restart at a lower dose when the INR approaches therapeutic range. 1
Risk Assessment First
An INR of 6.2 places the patient in the 5-9 range, which carries significant bleeding risk. The risk of adverse events increases logarithmically above INR 5, with intracerebral bleeding risk doubling for every 1-point INR increase 2. However, the absolute daily risk of major bleeding remains relatively low—approximately 4.4% over 14 days for INRs >6.0 3.
Immediately assess for:
- Active bleeding (any site)
- High-risk bleeding factors: age >65 years, history of stroke or GI bleeding, renal insufficiency, anemia, concomitant antiplatelet agents or NSAIDs 1
- Need for urgent surgery or invasive procedures
Management Algorithm
If NO Bleeding and NO High-Risk Factors:
Primary approach: Omit the next 1-2 warfarin doses and restart at a reduced dose when INR falls into therapeutic range 1
- Recheck INR in 24-48 hours
- Expect INR to decrease to <4.0 within 48-72 hours in most patients 3
- Resume warfarin at a lower maintenance dose once INR approaches 2.0-3.0
If NO Bleeding but HIGH-RISK Factors Present:
Add oral vitamin K₁: 1.0-2.5 mg orally in addition to omitting warfarin 1
- Oral vitamin K₁ is more effective than simply withholding warfarin, lowering INR to <5 within 24 hours in 95% of patients 1
- This dose avoids warfarin resistance while providing faster reversal
- Recheck INR in 24 hours
If Active Bleeding Present:
The management escalates based on bleeding severity, but this requires immediate evaluation beyond the scope of simple INR management.
Important Caveats
Avoid routine vitamin K for uncomplicated cases: The 2012 ACCP guidelines suggest against routine vitamin K use for INR 4.5-10 without bleeding, as pooled data showed no difference in major bleeding rates (2% with vitamin K vs 0.8% without) 2. However, the older 2003 AHA/ACC guidelines support its use in high-risk patients 1.
Route matters: Oral vitamin K₁ is preferred over IV or subcutaneous routes. IV carries anaphylaxis risk, while subcutaneous absorption is unpredictable 1. Oral administration is predictably effective, safe, and convenient.
Avoid excessive vitamin K doses: High doses (≥10 mg) can cause warfarin resistance lasting up to a week 1. For INR 5-9, doses of 1.0-2.5 mg are sufficient 1.
Follow-Up Strategy
- Recheck INR within 24-48 hours initially
- Once stable in therapeutic range, resume standard monitoring intervals
- Investigate the cause of INR elevation (medication interactions, dietary changes, illness, non-adherence)
- Adjust maintenance warfarin dose—typically requires reduction of 10-20% from previous dose
The key principle: Balance the risk of bleeding against the risk of thromboembolism from over-correction. For most patients with INR 6.2 and no bleeding, conservative management with warfarin omission alone is appropriate, reserving vitamin K for those at higher bleeding risk.